๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized trial

โœ Scribed by Mesut Oktem; Derya Eroglu; Hilal B. Karahan; Nilgun Taskintuna; Esra Kuscu; Hulusi B. Zeyneloglu

Publisher
Springer Healthcare Communications
Year
2007
Tongue
English
Weight
231 KB
Volume
24
Category
Article
ISSN
0741-238X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Fluoxetine treatment of acral lick derma
Fluoxetine treatment of acral lick dermatitis in dogs: A placebo-controlled randomized double blind trial
โœ Dora Wynchank; Michael Berk ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 46 KB ๐Ÿ‘ 2 views

## The aim of the study was to assess the efficacy and tolerability of fluoxetine treatment of acral lick dermatitis (ALD) in dogs and to investigate ALD as an animal model of obsessive-compulsive disorder (OCD). Sixty-three dogs with ALD were treated with fluoxetine 20 mg daily, or placebo, for 6

A prospective randomized trial comparing
A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding
โœ Ramon Planas; Juan Carlos Quer; Jaume Boix; Jaume Canet; Manel Armengol; Eduard ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 645 KB

Somatostatin and endoscopic sclerotherapy are widely used in the treatment of acute variceal bleeding. Although objective evidence does exist about the advantages of either treatment, data comparing both procedures are scarce. In order to compare the effectiveness and safety of somatostatin and scle

A prospective randomized trial of doxoru
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
โœ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 481 KB ๐Ÿ‘ 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea